Stem cell transplantation for ischemic stroke. by Boncoraglio, Giorgio Battista et al.
Cochrane
Library
 
Cochrane Database of Systematic Reviews
 
Stem cell transplantation for ischemic stroke (Review)
 
  Boncoraglio GB, Ranieri M, Bersano A, Parati EA, Del Giovane C  
  Boncoraglio GB, Ranieri M, Bersano A, Parati EA, Del Giovane C. 
Stem cell transplantation for ischemic stroke. 
Cochrane Database of Systematic Reviews 2019, Issue 5. Art. No.: CD007231. 
DOI: 10.1002/14651858.CD007231.pub3.
 
  www.cochranelibrary.com  
Stem cell transplantation for ischemic stroke (Review)
 
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
T A B L E   O F   C O N T E N T S
HEADER......................................................................................................................................................................................................... 1
ABSTRACT..................................................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2
SUMMARY OF FINDINGS.............................................................................................................................................................................. 3
BACKGROUND.............................................................................................................................................................................................. 5
OBJECTIVES.................................................................................................................................................................................................. 5
METHODS..................................................................................................................................................................................................... 5
RESULTS........................................................................................................................................................................................................ 7
Figure 1.................................................................................................................................................................................................. 8
Figure 2.................................................................................................................................................................................................. 10
Figure 3.................................................................................................................................................................................................. 11
DISCUSSION.................................................................................................................................................................................................. 13
AUTHORS' CONCLUSIONS........................................................................................................................................................................... 13
ACKNOWLEDGEMENTS................................................................................................................................................................................ 13
REFERENCES................................................................................................................................................................................................ 14
CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 19
DATA AND ANALYSES.................................................................................................................................................................................... 35
Analysis 1.1. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 1 Neurologic impairment
(measured by NIHSS)............................................................................................................................................................................
36
Analysis 1.2. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 2 Neurologic impairment
(measured by NIHSS, by phase of disease).........................................................................................................................................
37
Analysis 1.3. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 3 Neurologic impairment
(measured by NIHSS, by route of administration)..............................................................................................................................
37
Analysis 1.4. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 4 Disability (measured by
mRS).......................................................................................................................................................................................................
38
Analysis 1.5. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 5 Disability (measured by mRS,
by phase of disease).............................................................................................................................................................................
38
Analysis 1.6. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 6 Disability (measured by mRS,
by route of administration)..................................................................................................................................................................
39
Analysis 1.7. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 7 Dependency (measured by
BI)...........................................................................................................................................................................................................
40
Analysis 1.8. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 8 Dependency (measured by
BI, by route of administration).............................................................................................................................................................
40
Analysis 1.9. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 9 Any cause of death.............. 40
Analysis 1.10. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 10 Severe worsening of
neurological deficit...............................................................................................................................................................................
41
Analysis 1.11. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 11 Infections......................... 41
Analysis 1.12. Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 12 Neoplastic transformation
of ischemic lesion at longer-term follow-up.......................................................................................................................................
42
APPENDICES................................................................................................................................................................................................. 42
WHAT'S NEW................................................................................................................................................................................................. 44
CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 45
DECLARATIONS OF INTEREST..................................................................................................................................................................... 45
DIFFERENCES BETWEEN PROTOCOL AND REVIEW.................................................................................................................................... 45
INDEX TERMS............................................................................................................................................................................................... 45
Stem cell transplantation for ischemic stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
i
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
[Intervention Review]
Stem cell transplantation for ischemic stroke
Giorgio Battista Boncoraglio1,2, Michela Ranieri1, Anna Bersano1, Eugenio A Parati1, Cinzia Del Giovane3
1Department of Neurology, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milano, Italy. 2PhD Program in Neuroscience, Università
di Milano – Bicocca, Monza, Italy. 3Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
Contact address: Giorgio Battista Boncoraglio, Department of Neurology, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Via Celoria
11, Milano, 20133, Italy. giorgio.boncoraglio@istituto-besta.it.
Editorial group: Cochrane Stroke Group
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 5, 2019.
Citation: Boncoraglio GB, Ranieri M, Bersano A, Parati EA, Del Giovane C. Stem cell transplantation for ischemic stroke. Cochrane
Database of Systematic Reviews 2019, Issue 5. Art. No.: CD007231. DOI: 10.1002/14651858.CD007231.pub3.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Stroke is a leading cause of morbidity and mortality worldwide, with very large healthcare and social costs, and a strong demand for alter-
native therapeutic approaches. Preclinical studies have shown that stem cells transplanted into the brain can lead to functional improve-
ment. However, to date, evidence for the benefits of stem cell transplantation in people with ischemic stroke is lacking. This is the first
update of the Cochrane review published in 2010.
Objectives
To assess the efficacy and safety of stem cell transplantation compared with control in people with ischemic stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (last searched August 2018), CENTRAL (last searched August 2018), MEDLINE (1966
to August 2018), Embase (1980 to August 2018), and BIOSIS (1926 to August 2018). We handsearched potentially relevant conference pro-
ceedings, screened reference lists, and searched ongoing trials and research registers (last searched August 2018). We also contacted in-
dividuals active in the field and stem cell manufacturers (last contacted August 2018).
Selection criteria
We included randomized controlled trials (RCTs) that recruited people with ischemic stroke, in any phase of the disease (acute, subacute
or chronic), and an ischemic lesion confirmed by computerized tomography or magnetic resonance imaging scan. We included all types
of stem cell transplantation, regardless of cell source (autograft, allograft, or xenograK; embryonic, fetal, or adult; from brain or other
tissues), route of cell administration (systemic or local), and dosage. The primary outcome was efficacy (assessed as neurologic impairment
or functional outcome) at longer term follow-up (minimum six months). Secondary outcomes included post-procedure safety outcomes
(death, worsening of neurological deficit, infections, and neoplastic transformation).
Data collection and analysis
Two review authors independently applied the inclusion criteria, assessed trial quality and risk of bias, and extracted data. If needed, we
contacted study authors for additional information. We performed random effects meta-analyses when two or more RCTs were available
for any outcome. We assessed the certainty of the evidence by using the GRADE approach.
Main results
In this updated review, we included seven completed RCTs with 401 participants. All tested adult human non-neural stem cells; cells were
transplanted during the acute, subacute, or chronic phase of ischemic stroke; administered intravenously, intra-arterially, intracerebrally,
or into the lumbar subarachnoid space. Follow-up ranged from six months to seven years. Efficacy outcomes were measured with the
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National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), or Barthel Index (BI). Safety outcomes included case
fatality, and were measured at the end of the trial.
Overall, stem cell transplantation was associated with a better clinical outcome when measured with the NIHSS (mean difference [MD]
-1.49, 95% confidence interval [CI] -2.65 to -0.33; five studies, 319 participants; low-certainty evidence), but not with the mRS (MD -0.42,
95% CI -0.86 to 0.02; six studies, 371 participants; very low-certainty evidence), or the BI (MD 14.09, 95% CI -1.94 to 30.13; three studies,
170 participants; very low-certainty evidence). The studies in favor of stem cell transplantation had, on average, a higher risk of bias, and
a sample size of 32 or fewer participants.
No significant safety concerns associated with stem cell transplantation were raised with respect to death (risk ratio [RR] 0.66, 95% CI 0.39
to 1.14; six studies, participants; low-certainty evidence).
We were not able to perform the sensitivity analysis according to the quality of studies, because all of them were at high risk of bias.
Authors' conclusions
Overall, in participants with ischemic stroke, stem cell transplantation was associated with a reduced neurological impairment, but not
with a better functional outcome. No obvious safety concerns were raised. However, these conclusions came mostly from small RCTs with
high risk of bias, and the certainty of the evidence ranged from low to very low. More well-designed trials are needed.
P L A I N   L A N G U A G E   S U M M A R Y
Stem cell transplantation for ischemic stroke
Review question
Is stem cell transplantation safe and more effective than conventional treatments in improving recovery after ischemic stroke?
Background
Stroke represents a leading cause of death and disability worldwide, with very large healthcare and social costs. Available therapies, tar-
geted to restore patency of the blood vessel, consist of intravenous thrombolysis (the breakdown of blood clots formed in blood vessels,
using medication) and endovascular mechanical thrombectomy (surgical removal of clot), administrated within a few hours of stroke
onset, to just a few selected patients. Preliminary studies of stem cell transplantation (injecting cells that may save or replace damaged
nerve tissue) could be safe and effective in ischemic stroke. However, information in humans is lacking. This review updates the previous
Cochrane Review on this topic (Boncoraglio 2010).
Study characteristics
We included randomized trials that recruited adults with ischemic stroke, at any time after onset. We included any kind of stem cell or
method of administration.
Key results
We identified seven randomized trials, involving 401 participants. Overall, stem cell transplantation was associated with a reduced neu-
rological impairment, but not with a better functional outcome. No safety concerns were raised.
Certainty of the evidence
The certainty of the evidence ranged from low to very low because of the risk of bias in the included studies, the lack of precision of the
results, and different designs. More well-designed randomized controlled trials are needed.
Stem cell transplantation for ischemic stroke (Review)
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Summary of findings for the main comparison.   Stem cell transplantation compared to conventional treatments for ischemic stroke
Stem cell transplantation compared to conventional treatments for ischemic stroke
Patient or population: ischemic stroke
Setting: hospital
Intervention: stem cell transplantation
Comparison: conventional treatments
Anticipated absolute effects (95% CI)Outcomes
Without
stem cell
transplan-
tation
With stem
cell trans-
plantation
Difference
Relative ef-
fect
(95% CI)
No of Par-
ticipants
(studies)
Certainty
of the evi-
dence
(GRADE)
Comments
Neurologic im-
pairment
(measured by
NIHSS; 0 to 42;
higher = worse)
Median
score = 5.9
- MD 1.49 lower
(2.65 lower to
0.33 lower)
- 319
(5 RCTs)
⊕⊕⊝⊝
Lowa,b
Four studies were at high risk of bias for blinding of
participants and personnel at high risk of bias. Het-
erogeneity: Tau2 = 1.13; Chi2 = 11.68, df = 4 (P = 0.02);
I2 = 66%
Disability
(measured by
mRS; 0 to 6;
higher = worse)
Median
score = 2.75
- MD 0.42 lower
(0.86 lower to
0.02 higher)
- 371
(6 RCTs)
⊕⊝⊝⊝
Very lowa,b,c
Five studies were at high risk of bias for blinding
of participants and personnel at high risk of bias.
Heterogeneity: Tau2 = 0.19; Chi2 = 18.12, df = 5 (P =
0.003); I2 = 72%. The confidence interval was wide.
Dependency
(measured by
BI; 0 to 100;
higher = better)
Median
score =
63.39
- MD 14.09 higher
(1.94 lower to
30.13 higher)
- 170
(3 RCTs)
⊕⊝⊝⊝
Very lowa,b,c
All studies were at high risk of bias for blinding of
participants and personnel at high risk of bias. Het-
erogeneity: Tau2 = 154.96; Chi2 = 9.04, df = 2 (P =
0.01); I2 = 78%. The confidence interval was wide and
crossed the line of no difference.
Study populationAny cause of
death
19.7% 13.0%
(7.7 to 22.4)*
6.7% fewer
(12 fewer to 2.8
more)
RR 0.66
(0.39 to
1.14)
371
(6 RCTs)
⊕⊕⊝⊝
Lowa,c
Five studies were at high risk of bias for blinding of
participants and personnel at high risk of bias. The
confidence interval was wide and crossed the line of
no difference.
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Severe wors-
ening of neuro-
logical deficit
8.9% 12.4%
(4.6 to 33.8)
3.5% more
(4.4 fewer to 24.9
more)
RR 1.39
(0.51 to 3.79
321
(4 RCTs)
⊕⊕⊝⊝
Lowa,c
Three studies were at high risk of bias for blinding of
participants and personnel at high risk of bias. The
confidence interval was wide and crossed the line of
no difference.
Infections 23.2% 18.6%
(12.5 to
27.2)
4.6% fewer
(10.7 fewer to 3.9
more)
RR 0.80
(0.54 to
1.17)
321
(4 RCTs)
⊕⊕⊝⊝
Lowa,c
Three studies were at high risk of bias for blinding of
participants and personnel at high risk of bias. The
confidence interval was wide and crossed the line of
no difference.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
BI: Barthel Index; CI: confidence interval; mRS: modified Rankin Score; MD: mean difference; NIHSS: National Institutes of Health Stroke Scale; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aBlinding of participants and personnel at high risk of bias in almost all studies
bHigh heterogeneity
cImprecision
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B A C K G R O U N D
This review is the first update of a previously published review (Bon-
coraglio 2010).
Description of the condition
After ischemic heart disease, stroke is the leading cause of morbid-
ity and mortality worldwide (Hankey 2017). About 85% of strokes
are ischemic, caused by the interruption of blood flow in a brain-
supplying artery; this leads to irreversible cell damage in the is-
chemic core, surrounded by a penumbra of surviving neurons. The
rescue of the ischemic penumbra influences the functional recov-
ery and represents the target of the available therapies (Hankey
2017; Powers 2018). In the last two decades, with the widespread
adoption of organized stroke units, some reperfusion interventions
given in the acute phase of ischemic stroke, such as intravenous
recombinant tissue plasminogen activator and endovascular me-
chanical thrombectomy for large artery occlusion, have improved
outcomes, including survival and residual disability (Hankey 2017;
Powers 2018). However, due to the restricted treatment window
and the selection criteria, only a minority of people can benefit
from these therapies (de Los Rios la Rosa 2012; Kim 2017). There-
fore, once brain damage has occurred, little can be done to improve
functional outcome, except for rehabilitation therapy and phar-
macological management of comorbidities, with very large health-
care and social costs. To date, the case fatality rate at five years is
50%, and 40% of stroke survivors are disabled (Hankey 2017), which
leads to a strong demand for alternative therapeutic approaches.
Description of the intervention
Following a large number of experimental studies that highlight-
ed the potential of stem cell transplantation as a novel thera-
peutic approach for stroke (STEPS 3 2014; Zhang 2009), over the
past 15 years, a series of small, safety and feasibility-focused stud-
ies have investigated the use of stem cell therapies in people
with stroke (Muir 2016). Various sources (xenogeneic, allogenic,
or autologous) and types (embryonic or fetal neural, umbilical
mesenchymal, bone marrow-derived mesenchymal, or peripheral
blood hematopoietic) of stem cells have been evaluated, in differ-
ent phases of disease (acute, subacute, or chronic), and with differ-
ent routes of administrations (intravenous, intra-arterial, or intrac-
erebral [Nagpal 2017]). STEPS 3 (Stem cells as an emerging para-
digm in stroke 3) provides suggestions to develop phase II/III clini-
cal trials in acute and chronic stroke (STEPS 3 2014), but currently,
exact recommendations about patient selection, cell type and dos-
ing, time window, end-points, and follow-up duration, do not exist.
How the intervention might work
Preclinical studies have demonstrated that various types of cell-
based therapies substantially improve stroke recovery (Zhang
2009). However, during the last 15 years, the understanding of
mechanisms of action has significantly advanced: rather than cell
replacement, the benefit of stem cell treatments in stroke seems to
result from indirect mechanisms, such as immunomodulation, in-
tended to suppress the postischemic inflammatory response, and
enhancement of the endogenous repair (Goldman 2016; Janowski
2015; Muir 2016; Zhang 2009). Trial paradigms are now focused on
two different approaches: neuroprotection in the acute phase, and
neurorestoration in the chronic phase (Borlongan 2016).
The early delivery of cells reduces acute tissue injury, modifying
the tissue environment, basically with a paracrine mode of action,
for example suppressing oxidative stress, inflammation, mitochon-
drial impairment, and apoptosis. In acute stroke, patients may be
in a critical state, and the minimally invasive intravenous or in-
tra-arterial delivery of stem cells is preferred. Pooled allogenic cells
manufactured by the industry are ready to use, and will migrate
close to the infarcted area due to peripheral chemoattractants
(Borlongan 2016; Muir 2016). Cells with an higher immunomodu-
lating potential, such as mesenchymal stem cells, are usually pre-
ferred (Janowski 2015).
A later delivery of cells during the recovery phase, when the
chemokine signaling has waned, requires a direct intracerebral im-
plantation close to the damaged areas. Neural stem cells have a
higher potential of engraftment within the brain, and are usual-
ly preferred in this phase (Janowski 2015). The engraftment is in-
tended to initiate brain remodeling by stimulating quiescent stem
cells to mount reparative processes, including angiogenesis, vas-
culogenesis, neurogenesis, and synaptogenesis (Borlongan 2016;
Muir 2016).
Why it is important to do this review
Stroke is a leading cause of morbidity and mortality worldwide,
with very large healthcare and social costs, and there is a strong
demand for alternative therapeutic approaches. To date, evidence
for the benefit and safety of stem cell transplantation in patients
with ischemic stroke is lacking. A systematic review of the available
clinical trials is needed to assess the benefit-to-risk profile of stem
cell transplantation in people with ischemic stroke compared with
control.
O B J E C T I V E S
To assess the efficacy and safety of stem cell transplantation com-
pared with control in people with ischemic stroke.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only included published and unpublished randomized con-
trolled trials (RCTs).
Types of participants
We included people with ischemic stroke, with an ischemic lesion
confirmed by computerized tomography (CT) or magnetic reso-
nance imaging (MRI) scan, in any phase of the disease, from acute
to chronic. This long time period allowed for the inclusion of stud-
ies investigating both the neuroprotective and neurorestorative ef-
fects of transplanted stem cells.
Types of interventions
We included all types of stem cell transplantation, regardless of cell
source, cell type, route of administration, or dosage. We excluded
studies with combined treatments.
Stem cell transplantation for ischemic stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Types of outcome measures
Primary outcomes
Efficacy (neurologic impairment or functional outcome – disability
or dependency, or both) at longer-term follow-up, assessed using
clinical outcome measures or validated international scales, for ex-
ample the National Institutes of Health Stroke Scale (NIHSS), the
modified Rankin Scale (mRS), or the Barthel Index (BI). We set six
months as the minimum follow-up period.
Secondary outcomes
We evaluated the following postprocedural safety outcomes:
• any cause of death within 30 days of the procedure, and there-
after;
• severe worsening of neurological deficit (increase of four points
on the NIHSS scale or equivalent) within 30 days of procedure,
and thereafter;
• infections within 30 days of the procedure, and thereafter;
• neoplastic transformation of ischemic lesion at longer fol-
low-up.
Search methods for identification of studies
See the Cochrane Stroke Group's search methods. We searched for
trials in all languages and arranged translation of relevant research
where necessary.
Electronic searches
We searched the Cochrane Stroke Group Trials Register, which was
last searched by the Information Specialist on 13 August 2018; the
Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Is-
sue 7) in the Cochrane Library (searched August 2018; Appendix
1); MEDLINE Ovid (1966 to August 2018; Appendix 2); Embase Ovid
(1980 to August 2018; Appendix 3); and BIOSIS Citation Index (1926
to August 2018; Appendix 4).
We also searched the following ongoing trials and research regis-
ters in (last searched August 2018):
• US National Institutes of Health Ongoing Trials Register Clinical-
Trials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch);
• Internet Stroke Center Stroke Trials Registry (www.strokecen-
ter.org/trials/).
Searching other resources
In an effort to identify further published, unpublished, and ongoing
trials we:
• handsearched the conference proceedings;
• screened reference lists of relevant papers;
• contacted individuals active in the field and stem cell manufac-
turers (Athersys, Celgene Cellular Therapeutics, ReNeuron, San-
Bio); we last contacted them in August 2018.
Data collection and analysis
Selection of studies
Two review authors (AB and MR) independently read titles and ab-
stracts (if available) of the identified references and eliminated ob-
viously irrelevant studies. We retrieved full-text articles for the ref-
erences that remained, and two review authors (AB and MR) inde-
pendently examined potentially relevant studies, using the prede-
termined criteria of whether:
• the study was a RCT;
• the participants had an ischemic stroke with an ischemic lesion
confirmed at neuroimaging, and the intervention was stem cell
transplantation;
• neurologic impairment, or disability or dependency, or both,
were measured at entry and at the minimum follow-up period
of six months, using validated international scales.
We ranked studies as excluded, included, or uncertain, using a
checklist. We resolved any disagreements through discussion with
a third review author (GBB).
We collected multiple reports on the same study, so that each
study, not each reference, was the final unit of interest in the review.
We recorded the selection process and completed a PRISMA flow
diagram (PRISMA 2009).
Data extraction and management
Two review authors (AB and MR) independently extracted data
from the included studies. We resolved discrepancies by discus-
sion. We used a standard data extraction form based on the one
recommended by the Cochrane Handbook for Systematic Reviews
of Interventions to extract the following information: first study au-
thor; year of publication; recruitment period; phase of the disease;
sample size; source and type of stem cell transplantation; route of
administration; timing of stem cell transplantation; outcome data;
and the follow-up period (Higgins 2011).
Assessment of risk of bias in included studies
Two review authors (AB and MR) independently assessed the risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by discussion, or by consultation with
another review author (GBB). We assessed risk of bias according to
the following domains:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other bias.
We graded the risk of bias for each domain as high, low, or unclear,
and provided information from the study report, together with jus-
tification of our judgment, in the 'Risk of bias' tables.
Stem cell transplantation for ischemic stroke (Review)
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Measures of treatment e8ect
For continuous outcome, we calculated the mean difference (MD)
and relative 95% confidence interval (CI) for studies using the same
scales, and the standardized mean difference (SMD) with its relative
95% CI if different scales were used; for dichotomous outcomes, we
calculated the relative risk (RR) and 95% CI.
Unit of analysis issues
The unit of analysis was the participant; we did not include clus-
ter-randomized trials.
Dealing with missing data
When we found data were missing or identified discrepancies in
study publications, we contacted the study authors to request fur-
ther information. Where intention-to-treat analyses were not possi-
ble from the published and unpublished data, we did on-treatment
(per protocol) analyses.
Assessment of heterogeneity
To quantify between-study heterogeneity, we used the I2 statistic.
If we found substantial heterogeneity (I2 > 75%), we explored the
reasons.
Assessment of reporting biases
If we had identified at least 10 studies for each outcome, we would
have assessed reporting bias using funnel plots.
Data synthesis
We combined the study results using a random-effects meta-analy-
sis. We estimated the weighted treatment effect and 95% CI across
trials for continuous outcomes, and pooled RR with its 95% CI for
dichotomous outcomes. We used Review Manager 5 for all data en-
try and analysis (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
For the primary outcomes, we considered the following prespeci-
fied subgroups.
• Type of participant:
* phase of disease: acute (within seven days of ischemic
stroke), subacute (between eight days and three months), or
chronic (more than three months after ischemic stroke).
• Type of treatment:
* source of stem cells: human or nonhuman; embryonic and fe-
tal; or adult, neural, or non-neural;
* route of administration: neurosurgery, intra-arterial, or intra-
venous.
We considered heterogeneity to be significant if I2 was greater than
75%; if so, we sought the potential reasons, e.g. different follow-up
period.
Sensitivity analysis
To test the robustness of the results, we had intended to undertake
a sensitivity analysis by incorporating or removing studies that we
assessed to be of lower or ambiguous methodological quality.
Summary of findings table
We presented the overall certainty of the evidence for efficacy out-
comes (neurologic impairment, disability, dependency), any cause
of death, severe worsening of neurological deficit, and infections.
We evaluted the overall certainty of the evidence according to the
GRADE approach (GRADE Working Group 2004). We created the
'Summary of findings' table using GRADEpro GDT (GRADEpro GDT).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of exclud-
ed studies; Characteristics of studies awaiting classification; Char-
acteristics of ongoing studies.
We included seven randomized trials of 401 participants with acute,
subacute, and chronic ischemic stroke, who had been treated with
stem cell transplantation.
Results of the search
We identified 6398 references from electronic databases and
through handsearching. Figure 1 shows the PRISMA study flow di-
agram. Of the 6398 records identified, we removed 751 duplicate
references to the same papers. We excluded a further 5560 refer-
ences because they were not relevant. After full-text review of the
remaining 87 references, referring to 74 studies, we excluded 43
studies that did not meet the eligibility criteria (see Excluded stud-
ies). For 12 studies that met the inclusion criteria, we were unable
to obtain published relevant data; therefore, we contacted authors
to obtain additional unpublished data, but we did not receive any
replies (see Studies awaiting classification). Twelve studies met the
inclusion criteria, but are currently ongoing (See Ongoing studies).
Therefore, we included six new studies in this version of the review,
along with one trial already included in the previous version, involv-
ing 401 participants (Boncoraglio 2010).
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Included studies
We identified seven trials that fulfilled the inclusion criteria (Bang
2005; Bhatia 2015; Chen 2014; Hess 2014; Jin 2016; Lee 2010; Prasad
2014).
All seven trials used adult human non-neural stem cells: five bone
marrow-derived mesenchymal/mononuclear cells (Bang 2005;
Bhatia 2015; Jin 2016; Lee 2010; Prasad 2014), one peripheral blood
stem cells (Chen 2014), and one multipotent adult progenitor cells
(Hess 2014).
In five studies, during the subacute phase, cells were transplanted
intravenously (Bang 2005; Lee 2010; Prasad 2014), intra-arterially
(Bhatia 2015), or into the lumbar subarachnoid space (Jin 2016). In
one study, cells were transplanted intravenously during the acute
phase (Hess 2014), and in one study, cells were transplanted intrac-
erebrally during the chronic phase (Chen 2014).
Follow-up ranged from six months (Bhatia 2015), to one year (Bang
2005; Chen 2014; Hess 2014; Prasad 2014), five years (Lee 2010), or
seven years (Jin 2016).
Efficacy outcomes were reported using the National Institutes of
Health Stroke Scale (NIHSS) in five studies (Bhatia 2015; Chen 2014;
Hess 2014; Jin 2016; Prasad 2014), the modified Rankin Scale (mRS)
in six studies (Bhatia 2015; Chen 2014; Hess 2014; Jin 2016; Lee
2010; Prasad 2014), and the Barthel Index (BI) in three studies (Bang
2005; Jin 2016; Prasad 2014). Safety outcomes included case fatal-
ity at end-of-trial in cases and controls in six studies (Bhatia 2015;
Chen 2014; Hess 2014; Jin 2016; Lee 2010; Prasad 2014), neurologi-
cal deterioration in four studies (Bhatia 2015; Hess 2014; Lee 2010;
Prasad 2014), infections in four studies (Bhatia 2015; Hess 2014; Lee
2010; Prasad 2014), and new neoplastic disease in two studies (Bha-
tia 2015; Lee 2010).
We reported detailed description of the included studies in the
Characteristics of included studies.
Excluded studies
We excluded 43 studies for the reasons described in the Char-
acteristics of excluded studies: 42 were not randomized con-
trolled trials (Banerjee 2014; Battistella 2011; Bhasin 2011; Bhasin
2013; CoBIS 2015; Friedrich 2012; Ghali 2016; Honmou 2011;
ISRCTN15677760; Kondziolka 2000; Li 2007; Lin 2008; Lu 2013;
Man 2006; Mendonça 2006; Mohamed Ibrahim 2016; Moniche
2012; Napgal 2016; NCT01297413; NCT02397018; NCT02795052;
NCT03296618; NCT03384433; PISCES 2016; PISCES II 2017; Prasad
2012; Qiao 2014; Rabinovich 2005; Savitz 2005; Savitz 2011; Shar-
ma 2014; Sinden 2009; Steinberg 2014; Suarez-Monteagudo 2009;
Taguchi 2015; Vahidy 2012; Wanamaker 2015; Wang 2007; Wang
2013; Yang 2005; Yang 2007; Zhang 2006), and one evaluated com-
bined treatments (Meng 2009). We did not exclude any study be-
cause of the lack of neuroimaging or measurement of the neurolog-
ical impairment at baseline.
Twelve studies did not publish or provide data relevant for this re-
view (see Characteristics of studies awaiting classification [ChiC-
TR-INR-16008908; Kondziolka 2005; NCT01310114; NCT01468064;
NCT01518231; NCT02378974; NCT02564328; NCT02605707;
NCT03176498; NCT03186456; Sych 2012; Yavagal 2015]).
A further 12 studies met the inclusion criteria, but are current-
ly ongoing, and are expected to enroll over 1300 participants
(see Characteristics of ongoing studies [Bhasin 2016; Detante
2013; Diez-Tejedor 2014; Honmou 2016; Kim 2013; Moniche 2015;
NCT02448641; NCT02580019; NCT03004976; NCT03545607; RESS-
TORE 2015; TREASURE 2018]).
Risk of bias in included studies
For full details, see the corresponding 'Risk of bias' tables in Char-
acteristics of included studies, and Figure 2 and Figure 3.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study
(green for low risk of bias, yellow for unclear risk of bias, and red for high risk of bias)
 
Allocation
All included trials explicitly stated that randomization occurred.
Five trials reported the method of randomization, and we judged
them at low risk of bias (Bang 2005; Chen 2014; Hess 2014; Lee 2010;
Prasad 2014); two did not report how participants were random-
ized, and we judged them at unclear risk of bias (Bhatia 2015; Jin
2016).
Allocation was adequately concealed in five trials, and we judged
them at low risk of bias (Bhatia 2015; Chen 2014; Hess 2014; Jin
2016; Prasad 2014). In one trial, after initial randomization to the
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treatment group, five of 15 participants refused, and were allocat-
ed to the control group (Bang 2005). In one study, after initial ran-
domization, 33 of 85 participants were not included in the study
(11 participants died early or underwent hopeless discharge with-
in four weeks after randomization, before the first boosting of stem
cells; and 22 were unwilling to participate) without mentioning al-
location (Lee 2010). We judged these two trials at high risk of bias.
Blinding
One trial was blinded to both participants and outcome assessors,
and we judged it at low risk of bias (Hess 2014). Due to the invasive
procedures required for autologous stem cell transplantation (i.e.
bone marrow aspiration or stereotaxic intracerebral implantation),
most of the included trails were blinded only to outcome asses-
sors, and not to participants (Bang 2005; Bhatia 2015; Chen 2014;
Lee 2010; Prasad 2014). Although this limitation cannot be avoid-
ed for ethical reasons, given its possible effect on participants, we
assessed these studies at high risk of bias. One trial did not report
blinding procedures for either the participants or for the assessors,
and we judged it at high risk of bias (Jin 2016).
Incomplete outcome data
All seven trials reported the numbers lost to follow-up. In one study,
40% of controls were lost, and we judged the study at high risk of
bias (Bang 2005); we judged the remaining six trials at low risk of
bias.
Selective reporting
In two of the included trials, primary outcomes listed in published
protocols were adequately reported in the results, and we judged
them at low risk of bias (Chen 2014; Prasad 2014). In two trials, the
primary outcomes listed in published protocols or interim publi-
cations were different from those reported in the results, and we
judged them at high risk of bias (Bhatia 2015; Hess 2014). In one tri-
al, the outcomes listed in the methods section were different from
those reported in the results, and we judged it at high risk of bias
(Jin 2016). In two of the trials, selective reporting bias was not clear
because the protocols were not available (Bang 2005; Lee 2010).
Other potential sources of bias
In one trial, relevant results of 22 participants randomized between
day 15 and 28 were not available (Bhatia 2015); the study authors
concluded that in this group, intra-arterial infusion of stem cells
was safe but without beneficial effect on stroke outcome. However,
we considered this a potential bias and judged it at high risk of bias.
In one trial, granulocyte-colony stimulating factor (G-CSF) was used
to increase the number of CD34+ peripheral blood stem cells; since
G-CSF may be neuroprotective in the acute phase, and this trial in-
cluded only participants with chronic stroke, this was not consid-
ered a potential bias. Therefore, we judged it at low risk of bias
(Chen 2014). We did not identify any other potential sources of bias
for the remaining five trials, so judged them at low risk of bias.
E8ects of interventions
See: Summary of findings for the main comparison Stem cell
transplantation compared to conventional treatments for ischemic
stroke
See: Summary of findings for the main comparison
Primary outcomes
Neurologic impairment
Five trials, with a total of 319 participants, used the NIHSS to mea-
sure this outcome at the end of follow-up (Bhatia 2015; Chen 2014;
Hess 2014; Jin 2016; Prasad 2014). Participants randomized to stem
cell transplantation had a significantly better outcome compared
with controls (mean difference [MD] -1.49, 95% confidence interval
[CI] -2.65 to -0.33; I2 = 66%; low-certainty evidence; Analysis 1.1). In
subgroup analysis by phase of disease and route of administration,
treatment in the chronic phase of stroke was more effective than
in the acute or subacute phase (Analysis 1.2), and neurosurgery (in-
tracerebral or lumbar subarachnoid administration) was more ef-
fective than intravenous or intra-arterial administration (Analysis
1.3). However, only one RCT, with 30 or fewer participants, was in-
cluded in each of these subgroup analyses.
Disability
Six trials, with a total of 371 participants, used the mRS to measure
this outcome at the end of follow-up (Bhatia 2015; Chen 2014; Hess
2014; Jin 2016; Lee 2010; Prasad 2014). Results for participants ran-
domized to stem cell transplantation were inconclusive compared
with controls (MD -0.42, 95% CI -0.86 to 0.02; I2 = 72%; very low-
certainty evidence; Analysis 1.4). In subgroup analysis by phase of
disease and route of administration, treatment during the chron-
ic phase was more effective than treatment during the acute and
subacute phase (Analysis 1.5), and neurosurgery (intracerebral or
lumbar subarachnoid administration) was more effective than in-
travenous or intra-arterial administration (Analysis 1.6). However,
only one RCT, with 30 or fewer participants, was included in each of
these subgroup analyses.
Dependency
Three trials, with a total of 170 participants, used the BI to measure
this outcome at the end of follow-up (Bang 2005; Jin 2016; Prasad
2014 - Analysis 1.7). The results were inconclusive between stem
cell transplantation and controls, but the heterogeneity across tri-
als was high (MD 14.09, 95% CI -1.94 to 30.13, I2 = 78%; very low-
certainty evidence; Analysis 1.7). We found inconclusive results
between groups in subgroup analysis by route of administration
(Analysis 1.8). In all three trials, participants were treated in the sub-
acute phase.
Secondary outcomes
Any cause of death
Death was reported in six trials, with a total of 371 participants
(Bhatia 2015; Chen 2014; Hess 2014; Jin 2016; Lee 2010; Prasad
2014). The results were inconclusive between stem cell transplan-
tation and controls (risk ratio [RR] 0.66, 95% CI 0.39 to 1.14, I2 = 0%;
Analysis 1.9).
Severe worsening of neurological deficit
This outcome was reported in four trials, with a total of 321 partic-
ipants (Bhatia 2015; Hess 2014; Lee 2010; Prasad 2014). The results
were inconclusive between stem cell transplantation and controls
(RR 1.39, 95% CI 0.51 to 3.79, I2 = 41%; Analysis 1.10).
Infections
This outcome was reported in four trials, with a total of 321 partic-
ipants (Bhatia 2015; Hess 2014; Lee 2010; Prasad 2014). The results
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were inconclusive between stem cell transplantation and controls
(RR 0.80, 95% CI 0.54 to 1.17, I2 = 0%; Analysis 1.11).
Neoplastic transformation
This outcome was reported in two trials, with a total of 72 partic-
ipants (Bhatia 2015; Lee 2010). The results were inconclusive be-
tween stem cell transplantation and controls (RR 1.13, 95% CI 0.11
to 11.53; Analysis 1.12).
Sensitivity analysis
We did not perform any sensitivity analyses according to the quality
of studies, because all of them were at high risk of bias.
D I S C U S S I O N
Summary of main results
We identified seven RCTs, involving 401 participants with ischemic
stroke, 188 of whom were treated with stem cell transplantation
and 213 of whom were controls. Overall, stem cell transplantation
was associated with a better clinical outcome when measured with
the National Institutes of Health Stroke Scale (NIHSS), but not with
the modified Rankin Scale (mRS) or the Barthel Index (BI). These re-
sults could be consistent with a small benefit of stem cell transplan-
tation, which could only be detected when we considered neuro-
logical impairment, not when we considered functional outcome.
In subgroup analysis by phase of disease and route of administra-
tion, treatment during the chronic phase was more effective than
treatment during the acute and subacute phase, and neurosurgery
(intracerebral or lumbar subarachnoid administration) was more
effective than intravenous or intra-arterial administration. Howev-
er, only one RCT, with 30 or fewer participants, was included in each
of these subgroup analyses. The high heterogeneity that we found
in the primary outcome analysis could be explained by the aver-
age high risk of bias (most of the included studies had two or more
sources of potential bias) and the different designs (phase of dis-
ease, route of administration, and duration of the follow-up) of the
included studies.
Of note, two of the included trials, both with the lower risk of bias,
treated 60 or more participants each with stem cells (Hess 2014;
Prasad 2014), whereas the remaining five trials, with higher risk of
bias on average, treated 16 or fewer participants with stem cells.
In both larger trials, stem cell transplantation did not significantly
influence clinical outcomes, whereas in three of the five smaller tri-
als, it did.
No significant safety concerns associated with stem cell transplan-
tation were raised.
Overall completeness and applicability of evidence
Our review was deliberately broad, and we sought to include tri-
als in which stem cells were transplanted in people with ischemic
stroke so that the review would inform future research. The trials
we identified were relevant to our review question. All seven trials
used adult human non-neural stem cells, and the results of this re-
view should not be extrapolated to other types of stem cells.
Quality of the evidence
Overall, five trials reported the method of randomization, five trials
adequately concealed the sequence of randomization, and six tri-
als reported that the treatment was blinded to outcome assessors;
only one was also blinded to participants. Five trials reported com-
plete outcome data. Selective reporting bias was excluded in only
two trials.
Using the GRADE approach, we assessed the certainty of the evi-
dence as low to very low for the primary outcomes. The main rea-
sons for downgrading the certainty of the evidence included risk of
bias in included trials, inconsistency, and imprecision.
Potential biases in the review process
We attempted to limit bias in the review process. This review in-
corporated extensive literature searches guided by the Cochrane
Stroke Group, and we sought unpublished and ongoing work by
contacting authors of included studies and other experts in the
field. Two review authors independently decided whether studies
should be included, and two review authors independently extract-
ed data. During the review process, we did not have any significant
disagreement.
In the included studies, there were few missing data, probably with
a minimum impact on our conclusions. However, the ongoing trials
aim to enroll over 1300 participants, and are likely to have an im-
portant influence in future. In the next update, we intend to com-
bine the three types of primary outcome measure into a single pri-
mary outcome.
Finally, the mRS is not usually analyzed as a continuous measure,
and so the results based on this statistic may be very insensitive.
Agreements and disagreements with other studies or
reviews
Another systematic review, which also included studies without a
comparator arm and non-randomized controlled studies, had simi-
lar results (Nagpal 2017). Our findings are consistent with previous-
ly published papers calling for more research to determine the ef-
fectiveness of stem cell transplantation for ischemic stroke.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Currently there is insufficient evidence to support or refute the use
of stem cell transplantation to treat ischemic stroke.
Implications for research
Given the high prevalence of long-term disability after stroke, more
research is urgently needed to identify new treatments. Stem cells
appear promising in animal models, but more well-designed clini-
cal trials are needed (STEPS 3 2014).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Single-blind, randomized, controlled, phase I/II clinical trial
Participants 30 participants with subacute cerebral infarction in the MCA territory and severe neurological deficit
Treatment 10, control 20
Treated between 32 and 61 days from stroke onset
Interventions Intravenous infusion of 2 boosts of 50 million culture-expanded autologous bone marrow mesenchy-
mal stem cells
Outcomes NIHSS score as an index of neurological deficit and BI and mRS as indices of functional recovery at the
end of the 12-month follow-up
Notes Corresponding author provided individual level data for BI at 12 months
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomly allocated by a blinded, independent co-ordinator,
using a randomization table
Allocation concealment
(selection bias)
High risk After initial randomization, 5 participants allocated to the mesenchymal stem
cell group 'refused' and were allocated to the control group
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Experimental procedures, such as bone marrow aspiration, were not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Neurological and functional outcomes were checked by a neurologist who was
blind to the group allocation and radiological data
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 8 participants from the control group were lost to follow-up at 6 months
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available
Bang 2005 
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Other bias Low risk Control participants were significantly younger than those of the mesenchy-
mal stem cell group
Bang 2005  (Continued)
 
 
Methods Single-blind, randomized, controlled clinical trial
Participants 20 participants with subacute ischemic stroke in the MCA territory and NIHSS > 7
Treatment 10, control 10
Treated between 8 and 15 days from stroke onset
Interventions Intra-arterial infusion of bone marrow–derived mononuclear cells (mean 6.1 million) into the ipsilateral
MCA
Outcomes Primary safety outcomes and secondary efficacy endpoints as combined mRS, BI, and NIHSS score at
the end of the 6-month follow-up
Notes Corresponding author provided individual level data for NIHSS and mRS at 6 months
In a second arm of the study, 22 participants were randomized between day 15 and 28; for these partici-
pants, relevant results were not available and therefore, were excluded from the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants were randomized, but the method of the random sequence gen-
eration was not specified
Allocation concealment
(selection bias)
Low risk Participants were correctly allocated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Experimental procedures, such as bone marrow aspiration, were not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk An experienced neurologist, blinded to the nature of intervention, did the clini-
cal evaluations
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Outcome data were complete
Selective reporting (re-
porting bias)
High risk Primary outcomes listed in interim publications were different from those re-
ported in the results
Other bias High risk Relevant results of the 22 participants randomized between day 15 and 28
were not available
Bhatia 2015 
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Methods Single-blind, randomized, controlled clinical trial
Participants 30 participants with chronic MCA infarction and neurological deficits of intermediate severity
Treatment 15, control 15
Treated between 6 months and 5 years from stroke onset
Interventions Subcutaneous granulocyte-colony stimulating factor injections (15 μg/kg/day) for 5 consecutive days,
followed by stereotaxic implantation of autologous 3 to 8 million CD34+ immunosorted peripheral
blood stem cells
Outcomes Improvements in stroke scales (NIHSS, European Stroke Scale, and European Stroke Scale Motor Sub-
scale) and functional outcomes measure (mRS) from baseline to the end of the 12-month follow-up
Notes None
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were assigned randomly (1:1) via SAS software to either the pe-
ripheral blood stem cells or the control groups
Allocation concealment
(selection bias)
Low risk Participants were correctly allocated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Experimental procedures (such as stereotaxic implantation) were not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All clinical information was assessed by clinician raters in a single-blinded
fashion (at clinical evaluation, each participant wore a hat to mask the surgical
scar on their skull)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Outcome data were complete
Selective reporting (re-
porting bias)
Low risk Primary outcomes listed in published protocols were adequately reported in
the results
Other bias Low risk Granulocyte-colony stimulating factor may be neuroprotective in the acute
phase, but this trial included participants treated between 6 months and 5
years from stroke onset
Chen 2014 
 
 
Methods Double-blind, randomized, placebo-controlled, phase II multicenter dose-escalation clinical trial.
Analysis was by intention-to-treat
Participants After safety assessments in 8 participants (6 treated with 400 million intravenous multipotent adult
progenitor cells, 2 with placebo), 129 participants with acute ischemic stroke involving MCA territory,
with NIHSS score 8 to 20, and infarct size between 5 and 100 cc3, were enrolled
Hess 2014 
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Treatment 67, control 62
Treated between 24 and 48 hours from stroke onset
Interventions Intravenous infusion of 1.200 million multipotent progenitor cells or placebo
Outcomes The primary efficacy endpoint combined the mRS, the BI, and change in NIHSS score from baseline,
and was evaluated at day 90, and at the end of the 12-month follow-up
Notes Corresponding author provided summary statistics for NIHSS and mRS at 12 months
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization, interactive voice and web-response sys-
tem
Allocation concealment
(selection bias)
Low risk Participants were correctly allocated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants and all trial personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Investigators and clinicians were blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Primary outcomes within day 90 were complete; at 1-year follow-up, 24 partic-
ipants were lost (9 treatment and 15 placebo)
Selective reporting (re-
porting bias)
High risk Primary outcomes listed in published protocols were different from those re-
ported in the results
Other bias Low risk Intravenous tissue-plasminogen activator and endovascular thrombectomy
were more frequent in the placebo group; mean baseline infarct size was larg-
er in the placebo group
Hess 2014  (Continued)
 
 
Methods Randomized, controlled clinical trial
Participants 20 participants with subacute cerebral infarction and NIHSS score between 5 and 30
Treatment 10, control 10
Treated between 3 weeks and 5 months from stroke onset
Interventions Subarachnoid infusion of a cell suspension containing 10 million autologous bone marrow mononu-
clear cells
Outcomes Various safety and efficacy outcomes through a 7-year follow-up
Jin 2016 
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Notes None
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants were randomized, but the method of the random sequence gen-
eration was not specified
Allocation concealment
(selection bias)
Low risk Participants were correctly allocated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Experimental procedures, such as bone marrow aspiration, were not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Not specified
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Outcome data were complete
Selective reporting (re-
porting bias)
High risk Outcomes listed in the methods section did not correspond with those report-
ed in the results, and NIHSS score reported in text and tables were different
Other bias Low risk None
Jin 2016  (Continued)
 
 
Methods Single-blind, randomized, controlled clinical trial
Participants 52 participants with MCA territory infarct and severe neurological deficit
Treatment 16, control 36
Treated between 4 and 9 weeks from stroke onset
Interventions Intravenous infusion of 2 boosts of 50 million culture-expanded autologous bone marrow mesenchy-
mal stem cells
Outcomes mRS for functional recovery at the end of the 12-month follow-up
Notes None
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomly allocated by a blinded, independent co-ordinator,
using a randomization table
Lee 2010 
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Allocation concealment
(selection bias)
High risk After initial random allocation of 85 participants to treatment groups, 11 par-
ticipants died or underwent hopeless discharge, and 22 refused, without re-
porting allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Experimental procedures, such as bone marrow aspiration, were not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The outcome was evaluated separately, by one of the authors who was blind-
ed to clinical information
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Outcome data were complete
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available
Other bias Low risk None
Lee 2010  (Continued)
 
 
Methods Single-blind, randomized, controlled clinical trial
Participants 120 participants with anterior circulation ischemic stroke
Treatment 60, control 60
Treated between 7 and 30 days from stroke onset
Interventions Intravenous infusion of a mean of 280 million autologous bone marrow mononuclear stem cells
Outcomes The primary efficacy endpoint were the mRS and the BI at day 180; NIHSS at day 365 was a secondary
outcome. The safety outcomes included death, adverse events (serious and non-serious), epileptiform
discharges in electroencephalography, and evidence of any new growth on PET scan at day 365
Notes Corresponding author provided data for NIHSS and mRS at 12 months
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomly assigned by a central computer, using permuted
block randomization in a 1:1 ratio
Allocation concealment
(selection bias)
Low risk After initial randomization, 2 participants allocated to bone marrow mononu-
clear stem cell group were not treated (1 participant withdrew and 1 partici-
pant was missed because of logistical difficulty)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Experimental procedures, such as bone marrow aspiration, were not blinded
Prasad 2014 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Follow up for all participants was done from the co-ordinating center, by a
trained and blinded assessor, unaware of participant group
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 1 treated participant and 1 control were lost at longer follow-up
Selective reporting (re-
porting bias)
Low risk Primary outcomes listed in published protocols were adequately reported in
the results
Other bias Low risk Infarct volume at baseline was higher in control arm than in bone marrow
mononuclear stem cell arm
Prasad 2014  (Continued)
BI: Barthel Index
MCA: middle cerebral artery
mRS: modified Rankin Score
NIHSS: National Institutes of Health Stroke Scale
PET: positron emission tomography
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Banerjee 2014 Not RCT
Battistella 2011 Not RCT
Bhasin 2011 Not RCT
Bhasin 2013 Not RCT
CoBIS 2015 Not RCT
Friedrich 2012 Not RCT
Ghali 2016 Not RCT
Honmou 2011 Not RCT
ISRCTN15677760 Not RCT
Kondziolka 2000 Not RCT
Li 2007 Not RCT
Lin 2008 Not RCT
Lu 2013 Not RCT
Man 2006 Not RCT
Mendonça 2006 Not RCT
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Study Reason for exclusion
Meng 2009 Combined treatments (conventional therapy, filgrastim,
MSCs, filgrastim + MSCs)
Mohamed Ibrahim 2016 Not RCT
Moniche 2012 Not RCT
Napgal 2016 Not RCT
NCT01297413 Not RCT
NCT02397018 Not RCT
NCT02795052 Not RCT
NCT03296618 Not RCT
NCT03384433 Not RCT
PISCES 2016 Not RCT
PISCES II 2017 Not RCT
Prasad 2012 Not RCT
Qiao 2014 Not RCT
Rabinovich 2005 Not RCT
Savitz 2005 Not RCT
Savitz 2011 Not RCT
Sharma 2014 Not RCT
Sinden 2009 Not RCT
Steinberg 2014 Not RCT
Suarez-Monteagudo 2009 Not RCT
Taguchi 2015 Not RCT
Vahidy 2012 Not RCT
Wanamaker 2015 Not RCT
Wang 2007 Not RCT
Wang 2013 Not RCT
Yang 2005 Not RCT
Yang 2007 Not RCT
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Study Reason for exclusion
Zhang 2006 Not RCT
RCT: randomized controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomized parallel controlled trial
Participants 62 participants with NIHSS scores between 15 and 25, 1 to 3 months after onset of ischemic stroke
Interventions Intrathecal injection of allogenic bone marrow-derived mesenchymal stem cells
Outcomes Efficacy evaluated with mRS scale, NIHSS, infarct volume and mortality within 13 months after
treatment
Notes  
ChiCTR-INR-16008908 
 
 
Methods RCT
Participants 18 participants with fixed motor deficits, 1 to 6 years following a basal ganglia ischemic or hemor-
rhagic stroke
Interventions Stereotactic implantation of cultured neuronal cells produced from the NT2/D1 cell line derived
from a human teratocarcinoma
Outcomes Efficacy evaluated with European Stroke Scale motor score, Fugl-Meyer, Action Research Arm Test,
Stroke Impact Scale scores and the results of other motor, neuropsychological and functional tests
at 6 months
Notes Separated results for ischemic and hemorrhagic stroke participants were not available from the
publications
Kondziolka 2005 
 
 
Methods Randomized controlled dose-escalation trial
Participants 44 participants with acute ischemic stroke
Interventions Intravenous infusion of human placenta-derived cells (PDA001)
Outcomes Safety and tolerability up to 2 years
Notes  
NCT01310114 
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Methods RCT
Participants 20 participants with acute cerebral infarct within the MCA territory and severe neurological deficit
Interventions Intravenous infusion of autologous transplantation of ex vivo expanded bone marrow stromal cells
and endothelial progenitor cells
Outcomes Safety and efficacy up to 1 year
Notes  
NCT01468064 
 
 
Methods RCT
Participants 40 participants with ischemic stroke in the internal carotid artery territory during the previous year
Interventions Intrarterial infusion of autologous Peripheral Hematopoietic Stem Cell
Outcomes Safety and efficacy up to 1 year
Notes  
NCT01518231 
 
 
Methods Randomized controlled dose-escalation trial
Participants 18 participants within 7 days of onset of ischemic stroke
Interventions Intravenous infusion of Cordstem-ST
Outcomes Safety and efficacy up to 6 months
Notes  
NCT02378974 
 
 
Methods RCT
Participants 40 participants with chronic ischemic stroke (between 6 and 60 months after stroke)
Interventions Intravenous infusion of autologous bone marrow mesenchymal stem cells
Outcomes Safety and efficacy up to 1 year
Notes  
NCT02564328 
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Methods RCT
Participants 30 participants with chronic ischemic stroke (between 6 and 60 months after stroke)
Interventions Intravenous infusion of autologous endothelial progenitor cells
Outcomes Safety and efficacy up to 1 year
Notes  
NCT02605707 
 
 
Methods RCT
Participants 40 participants with ischemic stroke, in the convalescent period
Interventions Intravenous infusion of allogeneic umbilical cord mesenchymal stem cells
Outcomes Efficacy up to 6 months
Notes  
NCT03176498 
 
 
Methods RCT
Participants 40 participants with acute ischemic stroke
Interventions Intravenous infusion of allogeneic umbilical cord mesenchymal stem cells
Outcomes Safety and efficacy up to 26 weeks
Notes  
NCT03186456 
 
 
Methods RCT
Participants 27 participants with brain infarction, 11 in the treatment group and 16 in the control group, treated
3 months after onset of stroke
Interventions Transplantation of hematopoietic and non-hematopoietic mesenchymal and ectodermal fetal
stem cells, harvested from germ layers of internal organs of 4 to 8 week-old fetuses
Outcomes Evaluation of cognitive status (MMSE), frontal lobe dysfunction (FAB), and brain perfusion (tran-
scranial doppler)
Notes  
Sych 2012 
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Methods Randomized, sham-controlled clinical trial
Participants Participants with anterior circulation ischemic stroke, treated between 9 and 19 days after onset of
stroke
Interventions Intracarotid infusion of autologous bone marrow cells (ALD-401)
Outcomes Safety, efficacy and reduction in stroke volume at 1 year
Notes  
Yavagal 2015 
FAB: Frontal Assessment Battery
MCA: middle cerebral artery
MMSE: Mini Mental State Examination
mRS: modified Rankin Score
NIHSS: National Institutes of Health Stroke Scale
RCT: randomized controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Intravenous bone marrow-derived mononuclear stem cells in chronic ischemic stroke
Methods Randomized, controlled clinical trial
Participants 20 participants with chronic motor deficit from ischemic stroke
Interventions Intravenous infusion of bone marrow derived mononuclear stem cells (mean 60 to 70 million) or
placebo
Outcomes Efficacy evaluated with Fugl Meyer scale, modified BI, Medical Research Council Grade, Ashworth
Tone Scale
Starting date 2014
Contact information Prof MV Padma Srivastava, Department of Neurology, All India Institute of Medical Sciences, New
Delhi, India
Notes Interim analysis of safety, feasibility and efficacy at 8 weeks was published; follow-up is ongoing
Bhasin 2016 
 
 
Trial name or title Intravenous Stem cells after Ischemic Stroke (ISIS)
Methods Randomized, controlled, open clinical trial
Participants 31 participants with subacute ischemic stroke
Interventions Intravenous injection of low dose (100 million) or high dose (300 million) of autologous bone mar-
row mesenchymal stem cells; control group without intervention nor placebo
Detante 2013 
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Outcomes Functional recovery and neuroradiological outcome by multimodal MRI (anatomic, activation, va-
soreactivity, functional, and structural connectivity)
Starting date 2010
Contact information Dr Olivier Detante, University Hospital, Grenoble, France
Notes 3 participants did not receive the treatment because of karyotype abnormalities during cell cul-
ture; recruitment is complete, 2-year follow-up is ongoing
Detante 2013  (Continued)
 
 
Trial name or title AMASCIS-01
Methods Double-blind, randomized, controlled, phase II clinical trial
Participants 19 participants with acute or subacute ischemic stroke, and NIHSS between 8 and 20
Interventions Intravenous administration of allogeneic mesenchymal stem cells from adipose tissue (1 million /
kg) within the first 2 weeks after the onset of stroke symptoms
Outcomes Safety and efficacy analysis (mRS, NIHSS, size of infarct, and biochemical markers)
Starting date 2014
Contact information Dr Exuperio Diez-Tejedor, University Hospital La Paz, Madrid, Spain
Notes  
Diez-Tejedor 2014 
 
 
Trial name or title Phase III clinical trial using autologous mesenchymal stem cells for stroke patients
Methods Double-blind, randomized, controlled clinical trial
Participants Participants with subacute supratentorial cerebral infarction
Interventions Intravenous infusion of auto-serum expanded bone marrow derived-autologous mesenchymal
stem cells within 40 days from onset
Outcomes Feasibility, safety, and efficacy of cell therapy
Starting date 2016
Contact information Dr Osam Honmou, Research Institute for Frontier Medicine, Sapporo Medical University, Japan
Notes  
Honmou 2016 
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Trial name or title STARTING-2
Methods Single-blind, randomized, open clinical trial
Participants 60 participants with acute, subacute, or chronic ischemic stroke, and moderate to severe neurolog-
ic deficit
Interventions Intravenous transplantation of autologous mesenchymal stem cells, expanded with autologous
serum
Outcomes Functional endpoints, based on categorical shiK in mRS, and neurologic deficits
Starting date 2012
Contact information Dr Oh Young Bang, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,
South Korea
Notes  
Kim 2013 
 
 
Trial name or title IBIS Trial
Methods Single-blind, randomized, controlled, phase II, multicenter, open clinical trial
Participants 76 participants with acute ischemic stroke of moderate to severe intensity (NIHSS 6 to 20), involv-
ing the MCA
Interventions Intra-arterial infusion of 2 or 5 millions/kg mononuclear autologous bone marrow stem cells
Outcomes Functional outcomes evaluated with mRS and BI
Starting date 2015
Contact information Dr Francisco Moniche, Hospitales Universitarios Virgen del Rocio, Seville, Spain
Notes  
Moniche 2015 
 
 
Trial name or title ACTIsSIMA
Methods Double-blind, randomized, controlled (interventional, sham-surgery), phase IIB clinical trial
Participants 156 participants with chronic motor deficit from ischemic stroke in subcortical region of MCA or
lenticulostriate artery
Interventions Stereotactic intracranial injection of 2.5 or 5 million modified stem cells (SB623) or placebo
Outcomes Proportion of participants whose Fugl-Meyer Motor scale improved by ≥ 10 points at month 6 from
baseline
NCT02448641 
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Starting date January 2016
Contact information Study Sponsor: SanBio, Inc
Principal Investigator: Gary Steinberg, Stanford Hospital and Clinics, School of Medicine
Notes  
NCT02448641  (Continued)
 
 
Trial name or title Umbilical cord derived mesenchymal stem cells treatment in ischemic stroke
Methods Randomized, controlled, phase IIa, open clinical trial
Participants Participants with subacute ischemic stroke and NIHSS < 24
Interventions Intravenous injection of a single dose of 2 × 107 human umbilical cord mesenchymal stem cells
once a week for 4 weeks
Outcomes Safety and efficacy assessed as comparison of NIHSS and mRS
Starting date 2016
Contact information Prof Duan Lian, Affiliated Hospital (307 Hospital), Academy of Military Medical Science, Beijing, Chi-
na
Notes  
NCT02580019 
 
 
Trial name or title Study of allogeneic umbilical cord blood infusion for adults with ischemic stroke (CoBIS 2)
Methods Double-blind, randomized, controlled, phase II, multicenter clinical trial
Participants 100 participants with acute ischemic stroke
Interventions A single intravenous infusion of umbilical cord blood or placebo
Outcomes Safety and efficacy analysis
Starting date 2017
Contact information Dr J Kurtzberg, Robertson Clinical and Translational Cell Therapy Program, Duke University, North
Carolina, US
Notes Stem cells are supposed to be responsible, at least in part, for the mechanism of action of the um-
bilical cord blood
NCT03004976 
 
 
Trial name or title MASTERS-2
NCT03545607 
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Methods Double-blind, randomized, placebo-controlled, phase III, multicenter clinical trial
Participants 300 participants with acute ischemic stroke
Interventions Intravenous infusion of 1200 million multipotent progenitor cells or placebo within 18 to 36 hours
from onset of stroke
Outcomes Efficacy endpoint, assessed with mRS, or combined mRS, BI, and NIHSS
Starting date 2018
Contact information Athersys Clinical Trials Group
Notes  
NCT03545607  (Continued)
 
 
Trial name or title RESSTORE
Methods Randomized, controlled, phase IIb, multicenter clinical trial
Participants 400 participants with ischemic stroke
Interventions Intravenous infusion of allogenic adipose tissue derived mesenchymal stem cells
Outcomes Safety and efficacy (functional recovery) using clinical rating scales, multimodal MRI, and blood
biomarkers
Starting date 2015
Contact information Dr Olivier Detante, University Hospital, Grenoble, France
Notes  
RESSTORE 2015 
 
 
Trial name or title TREASURE
Methods Double-blind, randomized, controlled, multicenter, phase II/III clinical trial
Participants 220 participants with acute ischemic stroke
Interventions Intravenous infusion of 1200 million multipotent progenitor cells or placebo within 18 to 36 hours
of onset of stroke
Outcomes Safety and efficacy (the primary efficacy endpoint combines the mRS, BI, and NIHSS)
Starting date 2017
Contact information Dr Kiyohiro Houkin, Hokkaido University Hospital, Sapporo, Japan
Notes  
TREASURE 2018 
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BI: Barthel Index
MCA: middle cerebral artery
MRI: magnetic resonance imaging
mRS: modified Rankin Score
NIHSS: National Institutes of Health Stroke Scale
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Stem cell transplantation versus conventional treatments
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Neurologic impairment (measured by
NIHSS)
5 319 Mean Difference (IV, Random,
95% CI)
-1.49 [-2.65, -0.33]
2 Neurologic impairment (measured by
NIHSS, by phase of disease)
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
2.1 Acute and subacute 4 289 Mean Difference (IV, Random,
95% CI)
-1.05 [-2.03, -0.07]
2.2 Chronic 1 30 Mean Difference (IV, Random,
95% CI)
-3.20 [-4.52, -1.88]
3 Neurologic impairment (measured by
NIHSS, by route of administration)
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.1 Intravenous 2 249 Mean Difference (IV, Random,
95% CI)
-0.47 [-1.65, 0.70]
3.2 Intracerebral 1 30 Mean Difference (IV, Random,
95% CI)
-3.20 [-4.52, -1.88]
3.3 Lumbar subarachnoid space 1 20 Mean Difference (IV, Random,
95% CI)
-2.0 [-3.19, -0.81]
3.4 Intra-arterial 1 20 Mean Difference (IV, Random,
95% CI)
-0.80 [-3.07, 1.47]
4 Disability (measured by mRS) 6 371 Mean Difference (IV, Random,
95% CI)
-0.42 [-0.86, 0.02]
5 Disability (measured by mRS, by phase of
disease)
6   Mean Difference (IV, Random,
95% CI)
Subtotals only
5.1 Acute and subacute 5 341 Mean Difference (IV, Random,
95% CI)
-0.39 [-0.97, 0.19]
5.2 Chronic 1 30 Mean Difference (IV, Random,
95% CI)
-0.60 [-0.90, -0.30]
6 Disability (measured by mRS, by route of ad-
ministration)
6   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
6.1 Intravenous 3 301 Mean Difference (IV, Random,
95% CI)
0.03 [-0.28, 0.34]
6.2 Intracerebral 1 30 Mean Difference (IV, Random,
95% CI)
-0.60 [-0.90, -0.30]
6.3 Lumbar subarachnoid space 1 20 Mean Difference (IV, Random,
95% CI)
-1.10 [-1.65, -0.55]
6.4 Intra-arterial 1 20 Mean Difference (IV, Random,
95% CI)
1.00 [-2.76, 0.76]
7 Dependency (measured by BI) 3 170 Mean Difference (IV, Random,
95% CI)
14.09 [-1.94, 30.13]
8 Dependency (measured by BI, by route of
administration)
3   Mean Difference (IV, Random,
95% CI)
Subtotals only
8.1 Intravenous 2 150 Mean Difference (IV, Random,
95% CI)
8.75 [-9.84, 27.35]
8.2 Lumbar subarachnoid space 1 20 Mean Difference (IV, Random,
95% CI)
24.20 [11.57, 36.83]
9 Any cause of death 6 371 Risk Ratio (M-H, Random,
95% CI)
0.66 [0.39, 1.14]
10 Severe worsening of neurological deficit 4 321 Risk Ratio (M-H, Random,
95% CI)
1.39 [0.51, 3.79]
11 Infections 4 321 Risk Ratio (M-H, Random,
95% CI)
0.80 [0.54, 1.17]
12 Neoplastic transformation of ischemic le-
sion at longer-term follow-up
2 72 Risk Ratio (M-H, Random,
95% CI)
1.13 [0.11, 11.53]
 
 
Analysis 1.1.   Comparison 1 Stem cell transplantation versus conventional
treatments, Outcome 1 Neurologic impairment (measured by NIHSS).
Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bhatia 2015 10 2 (1.1) 10 2.8 (3.5) 14.24% -0.8[-3.07,1.47]
Chen 2014 15 5.5 (1.8) 15 8.7 (1.9) 22.22% -3.2[-4.52,-1.88]
Hess 2014 67 4.3 (4.3) 62 4.2 (4.5) 20.37% 0.1[-1.42,1.62]
Jin 2016 10 4.3 (1.5) 10 6.3 (1.2) 23.52% -2[-3.19,-0.81]
Prasad 2014 60 4.8 (4.1) 60 5.9 (4.8) 19.65% -1.1[-2.7,0.5]
   
Total *** 162   157   100% -1.49[-2.65,-0.33]
Heterogeneity: Tau2=1.13; Chi2=11.68, df=4(P=0.02); I2=65.76%  
Favours stem cell transplantation 52.5-5 -2.5 0 Favours conventional treatments
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Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=2.51(P=0.01)  
Favours stem cell transplantation 52.5-5 -2.5 0 Favours conventional treatments
 
 
Analysis 1.2.   Comparison 1 Stem cell transplantation versus conventional treatments,
Outcome 2 Neurologic impairment (measured by NIHSS, by phase of disease).
Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.2.1 Acute and subacute  
Bhatia 2015 10 2 (1.1) 10 2.8 (3.5) 14.7% -0.8[-3.07,1.47]
Hess 2014 67 4.3 (4.3) 62 4.2 (4.5) 26.18% 0.1[-1.42,1.62]
Jin 2016 10 4.3 (1.5) 10 6.3 (1.2) 34.57% -2[-3.19,-0.81]
Prasad 2014 60 4.8 (4.1) 60 5.9 (4.8) 24.55% -1.1[-2.7,0.5]
Subtotal *** 147   142   100% -1.05[-2.03,-0.07]
Heterogeneity: Tau2=0.35; Chi2=4.65, df=3(P=0.2); I2=35.51%  
Test for overall effect: Z=2.11(P=0.04)  
   
1.2.2 Chronic  
Chen 2014 15 5.5 (1.8) 15 8.7 (1.9) 100% -3.2[-4.52,-1.88]
Subtotal *** 15   15   100% -3.2[-4.52,-1.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.74(P<0.0001)  
Test for subgroup differences: Chi2=6.52, df=1 (P=0.01), I2=84.67%  
Favours stem cell transplantation 52.5-5 -2.5 0 Favours conventional treatments
 
 
Analysis 1.3.   Comparison 1 Stem cell transplantation versus conventional treatments,
Outcome 3 Neurologic impairment (measured by NIHSS, by route of administration).
Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.3.1 Intravenous  
Hess 2014 67 4.3 (4.3) 62 4.2 (4.5) 52.2% 0.1[-1.42,1.62]
Prasad 2014 60 4.8 (4.1) 60 5.9 (4.8) 47.8% -1.1[-2.7,0.5]
Subtotal *** 127   122   100% -0.47[-1.65,0.7]
Heterogeneity: Tau2=0.09; Chi2=1.14, df=1(P=0.29); I2=12.16%  
Test for overall effect: Z=0.79(P=0.43)  
   
1.3.2 Intracerebral  
Chen 2014 15 5.5 (1.8) 15 8.7 (1.9) 100% -3.2[-4.52,-1.88]
Subtotal *** 15   15   100% -3.2[-4.52,-1.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.74(P<0.0001)  
   
1.3.3 Lumbar subarachnoid space  
Favours stem cell transplantation 52.5-5 -2.5 0 Favours conventional treatments
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Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Jin 2016 10 4.3 (1.5) 10 6.3 (1.2) 100% -2[-3.19,-0.81]
Subtotal *** 10   10   100% -2[-3.19,-0.81]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.29(P=0)  
   
1.3.4 Intra-arterial  
Bhatia 2015 10 2 (1.1) 10 2.8 (3.5) 100% -0.8[-3.07,1.47]
Subtotal *** 10   10   100% -0.8[-3.07,1.47]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
Test for subgroup differences: Chi2=9.96, df=1 (P=0.02), I2=69.88%  
Favours stem cell transplantation 52.5-5 -2.5 0 Favours conventional treatments
 
 
Analysis 1.4.   Comparison 1 Stem cell transplantation versus
conventional treatments, Outcome 4 Disability (measured by mRS).
Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bhatia 2015 10 1.3 (1.8) 10 2.3 (2.2) 5% -1[-2.76,0.76]
Chen 2014 15 2.1 (0.3) 15 2.7 (0.5) 23.79% -0.6[-0.9,-0.3]
Hess 2014 67 2.8 (1.3) 62 2.8 (1.3) 20.93% 0.01[-0.43,0.45]
Jin 2016 10 1.2 (0.4) 10 2.3 (0.8) 18.67% -1.1[-1.65,-0.55]
Lee 2010 16 4 (1.6) 36 4.6 (1.9) 11.13% -0.6[-1.6,0.4]
Prasad 2014 60 3.6 (1.4) 60 3.4 (1.2) 20.46% 0.2[-0.27,0.67]
   
Total *** 178   193   100% -0.42[-0.86,0.02]
Heterogeneity: Tau2=0.19; Chi2=18.12, df=5(P=0); I2=72.41%  
Test for overall effect: Z=1.89(P=0.06)  
Favours stem cell transplantation 21-2 -1 0 Favours conventional treatments
 
 
Analysis 1.5.   Comparison 1 Stem cell transplantation versus conventional
treatments, Outcome 5 Disability (measured by mRS, by phase of disease).
Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.5.1 Acute and subacute  
Bhatia 2015 10 1.3 (1.8) 10 2.3 (2.2) 8.03% -1[-2.76,0.76]
Hess 2014 67 2.8 (1.3) 62 2.8 (1.3) 26.12% 0.01[-0.43,0.45]
Jin 2016 10 1.2 (0.4) 10 2.3 (0.8) 24.06% -1.1[-1.65,-0.55]
Lee 2010 16 4 (1.6) 36 4.6 (1.9) 16.1% -0.6[-1.6,0.4]
Prasad 2014 60 3.6 (1.4) 60 3.4 (1.2) 25.7% 0.2[-0.27,0.67]
Subtotal *** 163   178   100% -0.39[-0.97,0.19]
Heterogeneity: Tau2=0.28; Chi2=15.09, df=4(P=0); I2=73.49%  
Test for overall effect: Z=1.31(P=0.19)  
Favours stem cell transplantation 52.5-5 -2.5 0 Favours conventional treatments
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Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
1.5.2 Chronic  
Chen 2014 15 2.1 (0.3) 15 2.7 (0.5) 100% -0.6[-0.9,-0.3]
Subtotal *** 15   15   100% -0.6[-0.9,-0.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.99(P<0.0001)  
Test for subgroup differences: Chi2=0.41, df=1 (P=0.52), I2=0%  
Favours stem cell transplantation 52.5-5 -2.5 0 Favours conventional treatments
 
 
Analysis 1.6.   Comparison 1 Stem cell transplantation versus conventional
treatments, Outcome 6 Disability (measured by mRS, by route of administration).
Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.6.1 Intravenous  
Hess 2014 67 2.8 (1.3) 62 2.8 (1.3) 47.42% 0.01[-0.43,0.45]
Lee 2010 16 4 (1.6) 36 4.6 (1.9) 9.59% -0.6[-1.6,0.4]
Prasad 2014 60 3.6 (1.4) 60 3.4 (1.2) 42.99% 0.2[-0.27,0.67]
Subtotal *** 143   158   100% 0.03[-0.28,0.34]
Heterogeneity: Tau2=0; Chi2=2.04, df=2(P=0.36); I2=2.05%  
Test for overall effect: Z=0.21(P=0.83)  
   
1.6.2 Intracerebral  
Chen 2014 15 2.1 (0.3) 15 2.7 (0.5) 100% -0.6[-0.9,-0.3]
Subtotal *** 15   15   100% -0.6[-0.9,-0.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.99(P<0.0001)  
   
1.6.3 Lumbar subarachnoid space  
Jin 2016 10 1.2 (0.4) 10 2.3 (0.8) 100% -1.1[-1.65,-0.55]
Subtotal *** 10   10   100% -1.1[-1.65,-0.55]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.89(P=0)  
   
1.6.4 Intra-arterial  
Bhatia 2015 10 1.3 (1.8) 10 2.3 (2.2) 100% -1[-2.76,0.76]
Subtotal *** 10   10   100% -1[-2.76,0.76]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.11(P=0.27)  
Test for subgroup differences: Chi2=15.79, df=1 (P=0), I2=81.01%  
Favours stem cell transplantation 52.5-5 -2.5 0 Favours conventional treatments
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Analysis 1.7.   Comparison 1 Stem cell transplantation versus
conventional treatments, Outcome 7 Dependency (measured by BI).
Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bang 2005 10 62 (20.8) 20 42.6 (23.6) 29.6% 19.4[2.87,35.93]
Jin 2016 10 87.5 (7.6) 10 63.3 (18.9) 34.06% 24.2[11.57,36.83]
Prasad 2014 60 63.9 (29.6) 60 63.6 (29.6) 36.34% 0.3[-10.29,10.89]
   
Total *** 80   90   100% 14.09[-1.94,30.13]
Heterogeneity: Tau2=154.96; Chi2=9.04, df=2(P=0.01); I2=77.89%  
Test for overall effect: Z=1.72(P=0.08)  
Favours conventional treatments 2010-20 -10 0 Favours stem cell transplantation
 
 
Analysis 1.8.   Comparison 1 Stem cell transplantation versus conventional
treatments, Outcome 8 Dependency (measured by BI, by route of administration).
Study or subgroup Stem cell trans-
plantation
Convention-
al treatments
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.8.1 Intravenous  
Bang 2005 10 62 (20.8) 20 42.6 (23.6) 44.26% 19.4[2.87,35.93]
Prasad 2014 60 63.9 (29.6) 60 63.6 (29.6) 55.74% 0.3[-10.29,10.89]
Subtotal *** 70   80   100% 8.75[-9.84,27.35]
Heterogeneity: Tau2=132.25; Chi2=3.64, df=1(P=0.06); I2=72.5%  
Test for overall effect: Z=0.92(P=0.36)  
   
1.8.2 Lumbar subarachnoid space  
Jin 2016 10 87.5 (7.6) 10 63.3 (18.9) 100% 24.2[11.57,36.83]
Subtotal *** 10   10   100% 24.2[11.57,36.83]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.76(P=0)  
Test for subgroup differences: Chi2=1.81, df=1 (P=0.18), I2=44.89%  
Favours conventional treatments 5025-50 -25 0 Favours stem cell transplantation
 
 
Analysis 1.9.   Comparison 1 Stem cell transplantation versus
conventional treatments, Outcome 9 Any cause of death.
Study or subgroup Stem cell trans-
plantation
Conventional
treatments
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bhatia 2015 1/10 2/10 5.85% 0.5[0.05,4.67]
Chen 2014 0/15 0/15   Not estimable
Hess 2014 5/67 9/62 27.16% 0.51[0.18,1.45]
Jin 2016 1/10 1/10 4.23% 1[0.07,13.87]
Lee 2010 4/16 21/36 36.68% 0.43[0.18,1.05]
Prasad 2014 8/60 5/60 26.08% 1.6[0.56,4.61]
   
Total (95% CI) 178 193 100% 0.66[0.39,1.14]
Favours stem cell transplantation 200.05 50.2 1 Favours conventional treatments
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Study or subgroup Stem cell trans-
plantation
Conventional
treatments
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 19 (Stem cell transplantation), 38 (Conventional treatments)  
Heterogeneity: Tau2=0; Chi2=3.97, df=4(P=0.41); I2=0%  
Test for overall effect: Z=1.48(P=0.14)  
Favours stem cell transplantation 200.05 50.2 1 Favours conventional treatments
 
 
Analysis 1.10.   Comparison 1 Stem cell transplantation versus conventional
treatments, Outcome 10 Severe worsening of neurological deficit.
Study or subgroup Stem cell trans-
plantation
Conventional
treatments
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bhatia 2015 1/10 0/10 9.03% 3[0.14,65.9]
Hess 2014 5/67 9/62 37.92% 0.51[0.18,1.45]
Lee 2010 2/16 1/36 14.37% 4.5[0.44,46.12]
Prasad 2014 10/60 5/60 38.67% 2[0.73,5.5]
   
Total (95% CI) 153 168 100% 1.39[0.51,3.79]
Total events: 18 (Stem cell transplantation), 15 (Conventional treatments)  
Heterogeneity: Tau2=0.41; Chi2=5.12, df=3(P=0.16); I2=41.37%  
Test for overall effect: Z=0.65(P=0.52)  
Favours stem cell transplantation 1000.01 100.1 1 Favours conventional treatments
 
 
Analysis 1.11.   Comparison 1 Stem cell transplantation versus conventional treatments, Outcome 11 Infections.
Study or subgroup Stem cell trans-
plantation
Conventional
treatments
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bhatia 2015 0/10 0/10   Not estimable
Hess 2014 25/67 29/62 87.36% 0.8[0.53,1.2]
Lee 2010 3/16 9/36 10.71% 0.75[0.23,2.41]
Prasad 2014 1/60 1/60 1.93% 1[0.06,15.62]
   
Total (95% CI) 153 168 100% 0.8[0.54,1.17]
Total events: 29 (Stem cell transplantation), 39 (Conventional treatments)  
Heterogeneity: Tau2=0; Chi2=0.04, df=2(P=0.98); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Favours stem cell transplantation 1000.01 100.1 1 Favours conventional treatments
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Analysis 1.12.   Comparison 1 Stem cell transplantation versus conventional treatments,
Outcome 12 Neoplastic transformation of ischemic lesion at longer-term follow-up.
Study or subgroup Stem cell trans-
plantation
Conventional
treatments
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bhatia 2015 0/10 0/10   Not estimable
Lee 2010 1/16 2/36 100% 1.13[0.11,11.53]
   
Total (95% CI) 26 46 100% 1.13[0.11,11.53]
Total events: 1 (Stem cell transplantation), 2 (Conventional treatments)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.1(P=0.92)  
Favours stem cell transplantation 1000.01 100.1 1 Favours conventional treatments
 
 
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
We used the following search strategy for CENTRAL.
ID Search Hits
#1 [mh ^”cerebrovascular disease”] or [mh ^”cerebral artery disease”] or [mh ^”cerebrovascular accident”] or [mh ^stroke] or [mh ^”ver-
tebrobasilar insufficiency”] or [mh ^”carotid artery disease”] or [mh “carotid artery obstruction”] or [mh “brain infarction”] or [mh “brain
ischemia”] or [mh “occlusive cerebrovascular disease”]
#2 [mh ^”stroke patient”] or [mh ^”stroke unit”]
#3 (isch?emi* NEAR/6 (stroke* or apoplex* or cerebral vasc* or cerebrovasc* or cva or attack*)):ti,ab,kw (Word variations have been
searched)
#4 ((brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or mid-
dle cerebr* or mca* or anterior circulation) NEAR/5 (isch?emi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*)):ti,ab,kw (Word
variations have been searched)
#5 {or #1-#4}
#6 [mh ^”cell therapy”] or somatic cell therapy”] or [mh ^”cell transplantation”] or [mh “stem cell transplantation”]
#7 [mh “stem cell”]
#8 ((stem or progenitor or embryo* or fetal or foetal or umbilical or bone marrow or cord blood) NEAR/5 (cell or cells)):ti,ab,kw (Word
variations have been searched)
#9 (cell NEAR/5 (transplant* or graK*)):ti,ab,kw (Word variations have been searched)
#10 (fibroblast* or myoblast*):ti,ab,kw (Word variations have been searched)
#11 [mh ^”cell transplantation”]
#12 {or #6-#11}
#13 #5 and #12
Appendix 2. MEDLINE search strategy
We used the following search strategy for MEDLINE.
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or carotid artery diseases/ or carotid artery
thrombosis/ or intracranial arterial diseases/ or cerebral arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp stroke/
2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle
cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. 1 or 2 or 3
5. cell transplantation/ or stem cell transplantation/ or cord blood stem cell transplantation/ or hematopoietic stem cell transplantation/
or mesenchymal stem cell transplantation/ or peripheral blood stem cell transplantation/
6. stem cells/ or adult stem cells/ or embryonic stem cells/ or fetal stem cells/ or fibroblasts/ or hematopoietic stem cells/ or myeloid
progenitor cells/ or erythroid progenitor cells/ or mesenchymal stem cells/ or multipotent stem cells/ or exp myoblasts/ or pluripotent
stem cells/ or totipotent stem cells/ or tumor stem cells/
7. exp cells/tr
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8. ((stem or progenitor or embryo$ or fetal or foetal or umbilical or bone marrow or cord blood) adj5 (cell or cells)).tw.
9. (cell adj5 (transplant$ or graK$)).tw.
10. (fibroblast$ or myoblast$).tw.
11. cell transplantation.jn.
12. 5 or 6 or 7 or 8 or 9 or 10 or 11
13. Randomized Controlled Trials as Topic/
14. Random Allocation/
15. Controlled Clinical Trials as Topic/
16. control groups/
17. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical
trials, phase iv as topic/
18. double-blind method/
19. single-blind method/
20. Placebos/
21. placebo effect/
22. Drug Evaluation/
23. Research Design/
24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
27. (random$ or RCT or RCTs).tw.
28. (controlled adj5 (trial$ or stud$)).tw.
29. (clinical$ adj5 trial$).tw.
30. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
31. (quasi-random$ or quasi random$ or pseudo-random$ or pseud or random$).tw.
32. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
33. placebo$.tw.
34. controls.tw.
35. exp animals/ not humans.sh.
36. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
37. exp animals/ not humans.sh.
38. 4 and 12 and 36
39. 38 not 37
Appendix 3. Embase search strategy
We used the following search strategy for Embase.
1. cerebrovascular disease/ or cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar insufficiency/ or carotid
artery disease/ or exp carotid artery obstruction/ or exp brain infarction/ or exp brain ischemia/ or exp occlusive cerebrovascular disease/
2. stroke patient/ or stroke unit/
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.
4. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle
cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
5. 1 or 2 or 3 or 4
6. cell therapy/ or somatic cell therapy/ or cell transplantation/ or exp stem cell transplantation/
7. exp stem cell/
8. ((stem or progenitor or embryo$ or fetal or foetal or umbilical or bone marrow or cord blood) adj5 (cell or cells)).tw.
9. (cell adj5 (transplant$ or graK$)).tw.
10. (fibroblast$ or myoblast$).tw.
11. cell transplantation.jn.
12. 6 or 7 or 8 or 9 or 10 or 11
13. Randomized Controlled Trial/
14. Randomization/
15. Controlled Study/
16. control group/
17. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical trial/
18. Crossover Procedure/
19. Double Blind Procedure/
20. Single Blind Procedure/ or triple blind procedure/
21. latin square design/
22. Parallel Design/
Stem cell transplantation for ischemic stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
43
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
23. Placebo/
24. Multicenter Study/
25. experimental design/ or experimental study/ or quasi experimental study/
26. experimental therapy/
27. drug comparison/ or drug dose comparison/
28. drug screening/
29. EVALUATION/ or "EVALUATION AND FOLLOW UP"/ or evaluation research/ or clinical evaluation/
30. METHODOLOGY/
31. "types of study"/
32. research subject/
33. Comparative Study/
34. "systematic review"/
35. Meta Analysis/
36. random$.tw.
37. (controlled adj5 (trial$ or stud$)).tw.
38. (clinical$ adj5 trial$).tw.
39. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
40. (surgical adj5 (group$ or subject$ or patient$)).tw.
41. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
42. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
43. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
44. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
45. (coin adj5 (flip or flipped or toss$)).tw.
46. latin square.tw.
47. versus.tw.
48. (cross-over or cross over or crossover).tw.
49. placebo$.tw.
50. sham.tw.
51. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
52. controls.tw.
53. (treatment$ adj6 order).tw.
54. (meta-analy$ or metaanaly$ or meta analy$ or systematic review or systematic overview).tw.
55. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or
37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
57. 5 and 12 and 55
58. 57 not 56
Appendix 4. BIOSIS search strategy
We used the following search strategy for BIOSIS.
You searched for: TOPIC: (stroke or cerebr*) AND TOPIC: (stem cell* or cell transplant*) AND TOPIC: (trial* or random* or placebo* or blind*)
Timespan: All years.
Indexes: BCI.
W H A T ' S   N E W
 
Date Event Description
23 February 2019 New citation required but conclusions
have not changed
Conclusions not changed
13 August 2018 New search has been performed Search strategy updated. Six new trials with 371 participants
with ischemic stroke added. Meta-analysis of data from RCTs
completed when at least two studies were available for each out-
come.
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